25 results
Thumbnail

D1.422 - Characterization of provocation-induced changes in transcription factors in the nasal mucosa of birch pollen-allergic and non-allergic individuals

Thumbnail

D1.425 - Impact of Early Postnatal Administration of Escherichia coli O83:K24:H31 on Immune System Maturation and Gut Barrier Function

Thumbnail

D1.429 - The major birch pollen allergen activates the NLRP3 inflammasome in THP1-ASC-GFP reporter cells

Thumbnail

D1.423 - Immunological mechanisms underlying pulmonary manifestations in pediatric long COVID patients

Thumbnail

D1.424 - Single-cell transcriptomic profiling of allergen-restimulated PBMCs reveals innate immune activation in equine insect bite hypersensitivity

Thumbnail

D1.427 - Exploring the role of lipids on initiation of allergenic response in innate lymphoid cells

Thumbnail

D1.428 - Immunomodulation of human PBMCs by peptide amphiphiles

Thumbnail

D1.430 - Extracellular vesicles isolated after cholinergic urticaria challenge carry MRGPRX2 and induce pro-inflammatory mast cell responses

Thumbnail

D1.431 - Distinct Immunophenotypic Signatures in Pediatric Allergic Disease: Clinical Utility of Methylation qPCR–Based Epigenetic TBNK Profiling

Thumbnail

D1.432 - Association Between Autoimmunity and Endocrinopathy in Patients with Common Variable Immunodeficiency

Thumbnail

D1.433 - DNA Ligase I Deficiency Masquerading as CVID-Like Phenotype: Implications for Long-Term Surveillance

Thumbnail

D1.434 - Phenotyping Common Variable Immunodeficiency by Immune Dysregulation at Diagnosis: A Descriptive Comparison of Baseline Clinical and Laboratory Findings

Thumbnail

D1.435 - A TSLP Tuft Cell-Treg Cell Circuit promotes Food Allergy

Thumbnail

D1.436 - Transfusion-Related Acute Lung Injury (TRALI) following plasma transfusion: A case report

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study